|
|
Reyataz (Atazanavir)
| Brand Name: |
Reyataz |
| Generic Name: |
Atazanavir, ATV |
| Adult Single Dose: |
Therapy-naive patients: two 200-mg capsules (once a day)
Therapy-
experienced patients: two 150-mg capsules plus one 100-mg
ritonavir capsule (once a day) |
| Food & Liquid Restrictions: |
Take with food |
| Drug Class: |
PI |
|
|
|
The Basics
- An Overview of Reyataz (Atazanavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- FAQs About Reyataz (Regularly Updated)
From The Body's "Ask the Experts" Forums
- Atazanavir (Reyataz) (March 28, 2008)
To read PDF, click here
From AIDS InfoNet
- Reyataz (Atazanavir Sulfate, ATV) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Reyataz (Atazanavir) Package Insert Revisions (January 16, 2008)
From U.S. Food and Drug Administration
- Patient Information About Reyataz (Atazanavir) (PDF) (December 2007)
From Bristol-Myers Squibb Company
- Reyataz (Atazanavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Atazanavir (Reyataz) (August 15, 2006)
From AIDS Treatment Data Network
- Labeling Changes for Atazanavir (Reyataz) (January 26, 2006)
To read PDF, click here
From U.S. Food and Drug Administration
- HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From The Body PRO
- Reyataz (Atazanavir) (May 2005)
To read PDF, click here
From The Center for AIDS
- Three New Drugs Approved by FDA (November/December 2003)
An overview of Fuzeon (enfuvirtide, T-20), Reyataz (atazanavir) and Emtriva (emtricitabine, FTC).
In Survival News, from AIDS Survival Project
- Access Information for T-20 (Fuzeon), Atazanavir (Reyataz) and FTC (Emtriva) (October 2003)
How to get information about receiving these new HIV medications through ADAPs and Patient Assistance Programs.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- The Bottom Line on T-20 (Fuzeon), Atazanavir (Reyataz) and FTC (Emtriva) (October 2003)
Bare-bones highlights of three of this year's new HIV medications.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Position Paper on Atazanavir (BMS-232623, Reyataz) (July 23, 2003)
In TAGline, from Treatment Action Group
- Two Pills Once a Day. No Cholesterol or Triglyceride Issues? You Say This Is a Protease Inhibitor? Atazanavir (Reyataz) Gains FDA Approval (Summer 2003)
In Resolute!, from PWA Coalition Colorado
- Atazanavir Briefing Document (PDF) (May 2003)
Submitted to the FDA in advance of its May 13 Antiviral Drugs Advisory Committee meeting.
From Bristol-Myers Squibb Company
- FDA Review Document: Reyataz (Atazanavir Sulfate) Capsules and Powder for Oral Use (April 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
News & Research
- New Pediatric Dosing Recommendations for Reyataz Capsules, Patients Ages 6 to 18 Years Old (March 26, 2008)
To read PDF, click here
From U.S. Food and Drug Administration
- Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People (February 6, 2008)
From The Body PRO
- Reyataz Monotherapy Study Stopped (October 2007)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- Bristol-Myers Squibb Receives FDA Approval for New Formulation of Antiretroviral Reyataz (October 24, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- New 300 mg Reyataz Capsule Approved (October 23, 2006)
From U.S. Food and Drug Administration
- Increased I50L Prevalence Found After Unboosted Atazanavir Use in PI-Treatment-Experienced Patients (August 17, 2006)
In XVI International AIDS Conference
- Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain (August 17, 2006)
In XVI International AIDS Conference
- Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Putting Atazanavir + Ritonavir on the Map (July/August 2005)
A study finds the combo is comparable to lopinavir/ritonavir in patients with some baseline protease inhibitor resistance.
From The Body PRO
- Atazanavir -- The Little PI That Could (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
- Do Not Combine Reyataz and Prilosec: News Summary (December 31, 2004)
In AIDS Treatment News, from AIDS Treatment News
- Atazanavir, With or Without Ritonavir, Should Not Be Coadministered With Proton Pump Inhibitors (December 20, 2004)
From U.S. Food and Drug Administration
- Atazanavir Has Similar Efficacy, Safety to Efavirenz (August 2, 2004)
Unlike most protease inhibitors, atazanavir appears not to increase cholesterol, triglycerides or blood-sugar levels, potentially making it a more attractive option for people at risk of developing cardiovascular disease, a Phase III study finds.
From aidsmap.com
- New Dosing Regimen for Ritonavir-Boosted Atazanavir in Treatment-Experienced Patients; Revisions Made to Packaging Insert (July 7, 2004)
From U.S. Food and Drug Administration
- Atazanavir and Side Effects (July 2004)
Two studies presented at CROI 2004 find atazanavir has a better side-effect profile than most protease inhibitors.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Can Atazanavir Reverse Body Fat Changes? (April 8, 2004)
Anecdotal evidence recently reported in the journal AIDS suggests that atazanavir (Reyataz) may treat lipodystrophy.
From aidsmap.com
- Atazanavir (Reyataz): New Recommendations if Combined With Tenofovir (Viread) -- and Warning on Viagra, Cialis, and Levitra (March 26, 2004)
New warnings on drug-drug interactions are noted in the prescribing information for atazanavir.
In AIDS Treatment News, from AIDS Treatment News
- Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Unboosted Atazanavir Better on Insulin Sensitivity Compared to Lopinavir/Ritonavir (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Atazanavir Begins to Lose Its Clout as Protease Mutations Rise (October 28, 2003)
From aidsmap.com
- Ritonavir-Boosted Atazanavir Demonstrates Comparable Viral Load Reduction to Kaletra (August 15, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
From U.S. Food and Drug Administration
- Little Lipodystrophy Seen With Either Atazanavir or Efavirenz (July 16, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Atazanavir in Treatment-Experienced Patients (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- FDA Approves a Once-Daily Protease Inhibitor for HIV Infection (July 14, 2003)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- New Protease Inhibitor Atazanavir (Reyataz) Approved (June 27, 2003)
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves First Once-Daily Protease Inhibitor for AIDS (June 23, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- FDA Grants Approval of BMS' Reyataz for Combination Therapy in HIV Treatment (June 23, 2003)
From U.S. Food and Drug Administration
- The FDA Recommends the Approval of Atazanavir, a New Protease Inhibitor (June 10, 2003)
A research review.
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Reyataz Dosing Options Discussed (June 2003)
Transcript excerpts from the May 13, 2003 FDA Antiviral Drugs Advisory Committee meeting on atazanavir.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Bristol-Myers Seen Winning Panel's Backing for HIV Drug (May 13, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Atazanavir at 108 Weeks, and After Nelfinavir (April 2003)
A summary of study results from CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Atazanavir Resistance: Use as Second- or Third-Line PI Should Not Be Ruled Out (April 1, 2003)
Evidence that this drug in development may be more than a first-line treatment.
From aidsmap.com
- Retroviruses Conference Clinical News: Interview With Cal Cohen, M.D. (March 14, 2003)
Dr. Cohen discusses starting antiretroviral therapy (tenofovir vs. d4T, efavirenz vs. nevirapine), new protease inhibitor information (atazanavir and fos-amprenavir, a.k.a. "908") and antiretroviral-associated cardiovascular problems (the D:A:D study).
In AIDS Treatment News, from AIDS Treatment News
- Ask Dr. Jeff: What's Up With Atazanavir? (Spring 2003)
Dr. Jeffrey T. Schouten provides an overview.
In STEP Perspective, from Seattle Treatment Education Project
- CROI 2003: Emerging HIV Therapies (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Pharmacokinetic Parameters of Atazanavir/Ritonavir When Combined to Tenofovir in HIV Infected Patients With Multiple Treatment Failures: A Substudy of Puzzle2-ANRS 107 Trial (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Anti-HIV Drug Updates -- Three Drugs on the Near Horizon (January 2003)
Research from Barcelona on T-20, atazanavir and emtricitabine.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Anti-HIV Drug Updates: Atazanavir -- A Protease Inhibitor With a Difference (January 2003)
In Project Inform Perspective, from Project Inform
- Longer-Term Atazanavir Data Shows Good Lipid Profile (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- New Anti-HIV Therapies: Atazanavir (January 2003)
From Project Inform
- Atazanavir Enters the Home Stretch (December 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Research From the 42nd ICAAC: Atazanavir (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Twelve Weeks of Atazanavir Treatment Reverses Nelfinavir-Associated Hyperlipidemia: Results From BMS AI424-044 (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- The Buzz: Drug Giant Bristol-Myers Squibb -- Atazanavir Moves Into the Spotlight While 083 Bites the Dust (July/August 2002)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Expanded Access Program for Atazanavir (May 2002)
To read PDF, click here
In What's New, from Project Inform
- Atazanavir: A New Protease Inhibitor (March 2002)
A summary of the atazanavir/nelfinavir study presented at the 9th Retrovirus Conference.
In Project Inform Perspective, from Project Inform
- Atazanavir: A Once-Daily Protease Inhibitor With a Superior Lipid Profile: Results of Clinical Trials Beyond Week 48 (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Once-Daily Atazanavir Plus Saquinavir Favorably Affects Total Cholesterol (TC) and Fasting Triglyceride (TG) Profiles in Patients Failing Prior PI Therapy (Trial AI424-009, Week 24) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Comparative Results (Phase II 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naive HIV-Positive Patients (AI424-008) (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Population Pharmacodynamic (PD) Assessment of the Safety and Antiretroviral Activity of BMS-232632 (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- AIDS Drug Could Be Easier on the Heart (November 2001)
In Body Positive, from Body Positive
- Additional Evidence for the Absence of Serum Lipid Elevations After 48-Week Treatment with Atazanavir (BMS-232632) in Treatment-Naive HIV-Positive Subjects (Trial AI424-008) (October 30, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- AI424-007: 48-Week Safety and Efficacy Results from a Phase II Study of a Once-Daily HIV-1 Protease Inhibitor (PI), BMS-232632 (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Next Protease Inhibitor in the Pipeline? (October 10, 2000)
Coverage of the 40th ICAAC Conference.
In STEP Ezine, from Seattle Treatment Education Project
- BMS-232632: Single and Multiple Oral Dose Safety and Pharmacokinetic Study in Healthy Volunteers (February 3, 1999)
Summary by Jim Thommes, M.D.
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- BMS-232632: Single and Multiple Oral Dose Safety and Pharmacokinetic Study in Healthy Volunteers (February 3, 1999)
Summary by Donald L. Kaminsky, M.D.
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Resistance Profile and Drug Combination Studies of an HIV-1 Protease Inhibitor BMS-232632 (February 3, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Anti-Viral Activity and Resistance Profile of an HIV-1 Protease Inhibitor BMS-232632 (September 25, 1998)
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
|
|
